Amitiza Hits Mark In Confirmatory Opioid-Induced Bowel Dysfunction Study
This article was originally published in The Pink Sheet Daily
Sucampo/Takeda’s constipation treatment Amitiza meets primary endpoint in Phase III study of OBD, with a clean safety profile. Sucampo now sets its sights on a supplemental NDA for a third indication.
You may also be interested in...
Although privately held Oceana’s two products – Solesta and Deflux – are regulated by FDA as Class III medical devices, Salix intends to market them with existing sales forces.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
Sucampo Pharmaceuticals requests arbitration to end its partnership with Takeda, claiming the company has failed to maximize sales of the constipation drug Amitiza.